Low-dose enoximone improves exercise capacity in chronic heart failure. Enoximone Study Group.

Lowes, B D; Higginbotham, M; Petrovich, L; DeWood, M A; Greenberg, M A; Rahko, P S; Dec, G W; LeJemtel, T H; Roden, R L; Schleman, M M; Robertson, A D; Gorczynski, R J; Bristow, M R

Lowes, B D; Higginbotham, M; Petrovich, L; DeWood, M A; Greenberg, M A; Rahko, P S; Dec, G W; LeJemtel, T H; Roden, R L; Schleman, M M; Robertson, A D; Gorczynski, R J; Bristow, M R.

Affiliation

Lowes BD; Heart Failure Treatment Program, University of Colorado Health Sciences Center, Denver, USA. Brian.Lowes@uchsc.edu

J Am Coll Cardiol ; 36(2): 501-8, 2000 Aug.

Article in En | MEDLINE | ID: mdl-10933364

Subject(s)

Enoximone/administration & dosage; Exercise Tolerance/drug effects; Heart Failure/physiopathology; Phosphodiesterase Inhibitors/administration & dosage; Adolescent; Adult; Aged; Aged, 80 and over; Clinical Trials, Phase II as Topic; Double-Blind Method; Electrocardiography, Ambulatory; Enoximone/adverse effects; Exercise Test; Female; Humans; Male; Middle Aged; Phosphodiesterase Inhibitors/adverse effects

Search on Google

XML

PubMed Links

Collection: 01-internacional Health context: 6_ODS3_enfermedades_notrasmisibles Database: MEDLINE Main subject: Phosphodiesterase Inhibitors / Exercise Tolerance / Enoximone / Heart Failure Type of study: Clinical_trials / Guideline Aspects: Patient_preference Limits: Adolescent / Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Language: En Journal: J Am Coll Cardiol Year: 2000 Document type: Article

Search on Google

XML

PubMed Links